Clinical targeting of the TNF and TNFR superfamilies

  title={Clinical targeting of the TNF and TNFR superfamilies},
  author={Michael Croft and Chris A Benedict and Carl F Ware},
  journal={Nature Reviews Drug Discovery},
Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
105 Citations
236 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 105 extracted citations


Publications referenced by this paper.
Showing 1-10 of 236 references

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30‐positive hematologic malignancies

  • Fanale, A M.
  • Clin. Cancer Res
  • 2012

Development of a human monoclonal antibody for potential therapy of CD27‐expressing lymphoma and leukemia

  • L Vitale
  • Clin. Cancer Res
  • 2012

Similar Papers

Loading similar papers…